Form 4 for RNTX Rein Therapeutics, Inc.

Accepted 2024-03-06 00:00:00 ET · period of report 2024-03-05 · accession 0000950170-24-027304 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-03-06	2024-03-05	RNTX	WINDSOR JAMES BRIAN	Pres, COO	M - OptEx	—	+2,000	7,122	+39%	—
D	2024-03-06	2024-03-05	RNTX	WINDSOR JAMES BRIAN	Pres, COO	M - OptEx	—	-2	0	-100%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-03-05	M	A	2,000	—	7,122	D	—	—	(F1) On March 5, 2024, the Issuer's outstanding Series X Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series X Preferred Stock") automatically converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"), subject to certain beneficial ownership limitations. By operation of the certificate of designation for the Series X Preferred Stock, each share of Series X Preferred Stock was converted into 1,000 shares of Common Stock for no consideration.
2	Derivative	Series X Non-Voting Convertible Preferred	2024-03-05	M	D	2	—	0	D	— · — to —	2,000 Common Stock	(F1) On March 5, 2024, the Issuer's outstanding Series X Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series X Preferred Stock") automatically converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"), subject to certain beneficial ownership limitations. By operation of the certificate of designation for the Series X Preferred Stock, each share of Series X Preferred Stock was converted into 1,000 shares of Common Stock for no consideration.